The potential role of GLP-1 receptor agonists in the management of psoriatic disease: a scoping review
GLP-1RAs represent a novel, multifaceted therapeutic option in PsD, targeting both metabolic and inflammatory components. Further clinical trials are warranted to define their role in comprehensive PsD management and validate their disease-modifying potential.
Authors
- Bruno Frediani (ORCID: https://orcid.org/0000-0002-9375-5984)
- Riccardo Terribili (ORCID: https://orcid.org/0009-0001-8777-1187)
- Luca Cantarini (ORCID: https://orcid.org/0000-0002-7352-1275)
- Stefano Gentileschi (ORCID: https://orcid.org/0000-0001-6658-1037)
- Carla Gaggiano (ORCID: https://orcid.org/0000-0003-1401-8343)
- Simona Buonanno
Institutions
- University of Siena (IT)
Publication Details
- Journal
- Inflammation Research
- Published
- 2025-11-21
- DOI
- https://doi.org/10.1007/s00011-025-02140-2
- Citations
- 2
- Primary Topic
- Psoriasis: Treatment and Pathogenesis
- Type
- article
- Field-Weighted Citation Impact
- 1.59